Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Saxagliptin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saxagliptin Anhydrous SCHEMBL988028 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL8269188 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL882684 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL17642049 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL988030 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL17168 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL23752173 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL14763515 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL1624269 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL15579932 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3078369-B1 | COATED TABLET FORMULATION AND METHOD | ASTRAZENECA AB (SE) | 2019-08-21 | — | — | EP | disclosed |
| US-20190247390-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
| EP-2298288-B1 | Coated tablet formulation and method | ASTRAZENECA AB (SE) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015144098-A1 | A PROCESS FOR PRODUCING SAXAGLIPTIN | ZENTIVA, K.S. (CZ) | 2015-10-01 | — | — | WO | disclosed |
| US-20150119345-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS | Lumena Pharmaceuticals, Inc. (US) | 2015-04-30 | — | — | US | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-20120283181-A1 | CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-08 | — | — | US | disclosed |
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110200672-A1 | COATED TABLET FORMULATION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090054303-A1 | CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| WO-2008098256-A1 | METHODS FOR IDENTIFYING PATIENTS WITH AN INCREASED LIKELIHOOD OF RESPONDING TO DPP-IV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-14 | — | — | WO | disclosed |
| US-7214702-B2 | Process for producing a dipeptidyl peptidase IV inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070072810-A1 | Agent for treating diabetes | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2007-03-29 | — | — | US | disclosed |
| US-20070072810-A1 | Agent for treating diabetes | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2007-03-29 | — | — | US | disclosed |
| WO-2005117841-A1 | COATED TABLET FORMULATION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005115982-A1 | PROCESS FOR PRODUCING A DIPEPTIDYL PEPTIDASE IV INHIBITOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005012249-A2 | ADAMANTYGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119345-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS | SLC10A2, SLC10A1, NR1H4 | DPP4 207/4885CYP3A4 1312/4885DPP8 251/4885 |
| US-20120283181-A1 | CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME | SLC5A1, DPP4, GLP1R | DPP4 2/4885CYP3A4 418/4885DPP8 11/4885 |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | GPR119, GLP1R, GPR4 | DPP4 5/4885CYP3A4 1884/4885DPP8 35/4885 |
| US-20070072810-A1 | Agent for treating diabetes | IAPP, DPP4, GLP1R | DPP4 2/4885CYP3A4 2599/4885DPP8 7/4885 |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | GPR119, GLP1R, GPR4 | DPP4 5/4885CYP3A4 1884/4885DPP8 35/4885 |
| US-20090054303-A1 | CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME | SLC5A1, DPP4, GLP1R | DPP4 2/4885CYP3A4 418/4885DPP8 11/4885 |
| US-20110200672-A1 | COATED TABLET FORMULATION AND METHOD | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 69/4885DPP8 5/4885 |
| US-20190247390-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SLC10A2, GPR119, GPBAR1 | DPP4 51/4885CYP3A4 2318/4885DPP8 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.